Excessive Daytime Sleepiness Market Sizewas valued at USD 5.2 Billion in 2022. The excessive daytime sleepiness market industry is projected to grow from USD 5.57 Billion in 2023 to USD 9.72 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.20% during the forecast period (2023 - 2032). Increase of population, awareness, healthcare expenditure diverse drug array and government reimbursement policies are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Within the excessive daytime sleepiness (EDS) market, a notable trend is the continuous advancement of Application modalities. Emerging therapies, such as novel medications targeting specific neurotransmitters or innovative approaches like neuromodulator techniques, are gaining attention. As researchers delve deeper into understanding the underlying causes of EDS, the development of more effective and targeted Applications is on the rise. This trend reflects a commitment to addressing the complexities of excessive daytime sleepiness with a diverse range of therapeutic options, providing patients with tailored and improved solutions beyond traditional medications. This factor drives the market CAGR.
Additionally, an evolving trend in the excessive daytime sleepiness market involves the integration of wearable technology for monitoring and managing sleep-related conditions. Wearable devices equipped with advanced sensors can track sleep patterns, monitor physiological parameters, and provide real-time data on sleep quality. This trend aligns with the growing demand for patient-centric solutions and facilitates more precise diagnostic measures. The incorporation of wearable technology not only aids in the accurate assessment of daytime sleepiness but also promotes a proactive approach to managing sleep disorders, fostering a trend towards personalized and data-driven healthcare interventions.
In response to the increasing prevalence of excessive daytime sleepiness and the need for accessible healthcare solutions, the market is witnessing a surge in telemedicine and virtual care platforms. Telehealth services allow patients to consult sleep specialists remotely, facilitating convenient access to expert advice and diagnostic evaluations. This trend is particularly relevant in the context of sleep disorders, as it overcomes geographical barriers and enhances patient engagement. The integration of virtual care platforms in the excessive daytime sleepiness market represents a shift towards more patient-centric and inclusive healthcare delivery, ensuring that individuals can receive timely and comprehensive care regardless of their location. For instance, in February 2023, Pharmanovia announced the expansion of its neurology portfolio via a new licensing agreement with Axsome Therapeutics, Inc. Sunosi (solriamfetol), a first-in-class drug used to increase alertness and reduce EDS in individuals with narcolepsy or obstructive sleep apnoea (OSA), was expected to be marketed exclusively by Pharmanovia in Europe and the Middle East and North Africa (MENA). Thus, driving the excessive daytime sleepiness market revenue.
The excessive Daytime Sleepiness market segmentation, based on Diseases includes Obstructive Sleep Apnea (OSA), Narcolepsy. The dominant category is Obstructive Sleep Apnea (OSA). This condition affects millions of individuals worldwide and is associated with various health complications, including cardiovascular diseases, hypertension, and impaired cognitive function. Due to its widespread prevalence and significant impact on overall health and well-being, OSA remains the primary focus of diagnosis, treatment, and management efforts within the Excessive Daytime Sleepiness market. Narcolepsy represents the fastest-growing category within the Excessive Daytime Sleepiness market. While narcolepsy is less common than OSA, its recognition and diagnosis have been increasing in recent years due to greater awareness among healthcare professionals and the general public. Additionally, advancements in diagnostic techniques and treatment options for narcolepsy have contributed to its rapid growth within the Excessive Daytime Sleepiness market
Figure 1: Excessive Daytime Sleepiness Market, by Diseases, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The excessive Daytime Sleepiness market segmentation, based on Treatment, includes Devices, Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate). The dominant category is Therapeutic Drugs, This encompasses a range of pharmaceutical interventions aimed at managing and alleviating symptoms associated with various sleep disorders contributing to excessive daytime sleepiness. Due to their widespread availability, established efficacy, and physician familiarity, therapeutic drugs remain the cornerstone of treatment strategies for managing sleep disorders and associated symptoms, making them the dominant category. Furthermore, Devices, particularly those related to therapy, represent the fastest-growing category in the Excessive Daytime Sleepiness market. Due to increasing awareness about sleep disorders and technological advancements in device design and functionality, the demand for diagnostic and therapeutic devices is expected to surge.
The excessive Daytime Sleepiness market segmentation, based on Distribution channels, includes Hospitals & Sleep Laboratories, Home Care Settings. The dominant category is Hospitals & Sleep Laboratories, These facilities serve as essential hubs for the diagnosis, treatment, and management of sleep disorders contributing to excessive daytime sleepiness. Hospitals with specialized sleep clinics and laboratories offer comprehensive sleep studies, including polysomnography and multiple sleep latency tests, to accurately diagnose conditions such as obstructive sleep apnea (OSA), narcolepsy, and restless legs syndrome. Home Care Settings emerge as the fastest-growing category in the distribution channels for the Excessive Daytime Sleepiness market. With the increasing emphasis on patient-centered care and the growing popularity of home-based medical services, there is a rising trend toward providing sleep disorder management and treatment options in the comfort of patients' homes.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American excessive daytime sleepiness market area will dominate this market, owing to an increased awareness and proactive initiatives in North America regarding the importance of sleep health and the consequences of untreated sleep disorders lead to higher rates of diagnosis and intervention. In addition, the growing number of establishing health clubs and fitness facilities will boost market growth in this region.
Further, the major countries studied in the market reportare The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure2: EXCESSIVE DAYTIME SLEEPINESS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europeexcessive daytime sleepiness market accounts for the second-largest market share due to the excessive daytime sleepiness, influenced by factors such as lifestyle changes and work-related stress. Further, the Germanexcessive daytime sleepiness market held the largest market share and the UK excessive daytime sleepiness market was the fastest growing market in the European region
The Asia-Pacific Excessive daytime sleepiness Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due toimproving healthcare infrastructure and the growing awareness of sleep-related issues contributes to an enhanced diagnosis and Application landscape.Moreover, China’sexcessive daytime sleepiness market held the largest market share, and the Indianexcessive daytime sleepiness market was the fastest growing market in the Asia-Pacific region.
Excessive daytime sleepiness Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the excessive daytime sleepiness market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, excessive daytime sleepiness industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the excessive Daytime Sleepiness industry to benefit clients and increase the market sector. In recent years, the excessive daytime sleepiness industry has offered some of the most significant advantages. Major players in the excessive daytime sleepiness market, including Teva Pharmaceutical Industries Ltd.,GE Healthcare ,Jazz Pharmaceuticals,CompumedicsFisher & Paykel Healthcare,BIOPROJET,BMC Medical Co. Ltd.,Avadel Pharmaceuticals plc ,Cadwell Laboratories Inc. Ltd ,GlaxoSmithKline plc ,Braebon Medical Corporation ,Pfizer and others, are attempting to increase market demand by investing in research and development operations.
Harmony Biosciences Holdings, Inc. was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania, USA. The company is dedicated to addressing unmet needs in sleep and CNS disorders, with a focus on bringing transformative Applications to patients.Harmony Biosciences is known for its emphasis on narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. The company has developed and commercialized medications specifically designed to address symptoms associated with narcolepsy. Harmony Biosciences Holdings, Inc. initiated a Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study.
NLS Pharma Ltd. is a biopharmaceutical company dedicated to advancing innovative Applications for central nervous system disorders, with a particular focus on narcolepsy. Privately held, the company is committed to addressing unmet medical needs in the field of neurological and psychiatric conditions through research, development, and the advancement of novel therapies. With a pipeline of drug candidates, NLS Pharma aims to contribute to improved outcomes for patients experiencing symptoms such as excessive daytime sleepiness and cataplexy. NLS pharma Ltd. reported that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion to grant Orphan Drug Designation (ODD) for Mazindol ER (Quilience) for the Application of idiopathic hypersomnia (IH).
Key Companies in the excessive daytime sleepiness market include
Excessive daytime sleepiness Industry Developments
August 2021:For a new indication of Xywav, Jazz Pharmaceuticals Plc. received USFDA approval (calcium, magnesium, potassium, and sodium oxybates). It is an oral solution used to treat adult patients with idiopathic hypersomnia. It is the first medication that the USFDA has approved for unique use in idiopathic hypersomnia.
March 2019:Jazz Pharmaceuticals Plc. received FDA approval for a Sunosi (solriamfetol). The first and only dual-acting dopamine and norepinephrine reuptake inhibitor that has been authorized to treat excessive daytime sleepiness linked to narcolepsy or obstructive sleep apnea.
| Report Attribute/Metric | Details |
| Market Size2022 | USD 5.2Billion |
| Market Size 2023 | USD 5.57Billion |
| Market Size2032 | USD 9.72Billion |
| Compound Annual Growth Rate (CAGR) | 7.20%(2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Diseases, Treatment, Distribution channels and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd.,GE Healthcare ,Jazz Pharmaceuticals, Compumedics Fisher&Paykel Healthcare, BIOPROJET, BMC Medical Co. Ltd., Avadel Pharmaceuticals plc ,Cadwell Laboratories Inc. Ltd |
| Key Market Opportunities | · Increase of population, awareness, healthcare expenditure diverse drug array. |
| Key Market Dynamics | · Government reimbursement policies |
Frequently Asked Questions (FAQ) :
The excessive Daytime Sleepiness market size was valued at USD 5.2Billion in 2022.
The global market is projected to grow at a CAGR of 7.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Teva Pharmaceutical Industries Ltd., GE Healthcare, Jazz Pharmaceuticals, Compumedics Fisher&Paykel Healthcare, BIOPROJET, BMC Medical Co. Ltd., Avadel Pharmaceuticals plc, Cadwell Laboratories Inc. Ltd, GlaxoSmithKline plc, Braebon Medical Corporation, and Pfizer.
The Obstructive Sleep Apnea (OSA) category dominated the market in 2022.
The Hospitals & Sleep Laboratories CATEGORY had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
